1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Passive Transdermal Drug Delivery Revenue
1.4 Market Analysis by Type
1.4.1 Global Passive Transdermal Drug Delivery Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Microfluidics
1.4.3 Smart Pill Technology (SPT)
1.5 Market by Application
1.5.1 Global Passive Transdermal Drug Delivery Market Share by Application: 2021-2026
1.5.2 Clinic
1.5.3 Hospital
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Passive Transdermal Drug Delivery Market
1.8.1 Global Passive Transdermal Drug Delivery Market Status and Outlook (2015-2026)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Passive Transdermal Drug Delivery Production Capacity Market Share by Manufacturers (2015-2020)
2.2 Global Passive Transdermal Drug Delivery Revenue Market Share by Manufacturers (2015-2020)
2.3 Global Passive Transdermal Drug Delivery Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Passive Transdermal Drug Delivery Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Passive Transdermal Drug Delivery Sales Volume Market Share by Region (2015-2020)
3.2 Global Passive Transdermal Drug Delivery Sales Revenue Market Share by Region (2015-2020)
3.3 North America Passive Transdermal Drug Delivery Sales Volume
3.3.1 North America Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.3.2 North America Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.4 East Asia Passive Transdermal Drug Delivery Sales Volume
3.4.1 East Asia Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.4.2 East Asia Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.5 Europe Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.5.1 Europe Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.5.2 Europe Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.6 South Asia Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.6.1 South Asia Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.6.2 South Asia Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.7 Southeast Asia Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.7.1 Southeast Asia Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.7.2 Southeast Asia Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.8 Middle East Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.8.1 Middle East Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.8.2 Middle East Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.9 Africa Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.9.1 Africa Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.9.2 Africa Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.10 Oceania Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.10.1 Oceania Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.10.2 Oceania Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.11 South America Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.11.1 South America Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.11.2 South America Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
3.12 Rest of the World Passive Transdermal Drug Delivery Sales Volume (2015-2020)
3.12.1 Rest of the World Passive Transdermal Drug Delivery Sales Volume Growth Rate (2015-2020)
3.12.2 Rest of the World Passive Transdermal Drug Delivery Sales Volume Capacity, Revenue, Price and Gross Margin (2015-2020)
4 North America
4.1 North America Passive Transdermal Drug Delivery Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Passive Transdermal Drug Delivery Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Passive Transdermal Drug Delivery Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Passive Transdermal Drug Delivery Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Passive Transdermal Drug Delivery Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Passive Transdermal Drug Delivery Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Passive Transdermal Drug Delivery Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Passive Transdermal Drug Delivery Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Passive Transdermal Drug Delivery Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Passive Transdermal Drug Delivery Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Passive Transdermal Drug Delivery Sales Volume Market Share by Type (2015-2020)
14.2 Global Passive Transdermal Drug Delivery Sales Revenue Market Share by Type (2015-2020)
14.3 Global Passive Transdermal Drug Delivery Sales Price by Type (2015-2020)
15 Consumption Analysis by Application
15.1 Global Passive Transdermal Drug Delivery Consumption Volume by Application (2015-2020)
15.2 Global Passive Transdermal Drug Delivery Consumption Value by Application (2015-2020)
16 Company Profiles and Key Figures in Passive Transdermal Drug Delivery Business
16.1 3M
16.1.1 3M Company Profile
16.1.2 3M Passive Transdermal Drug Delivery Product Specification
16.1.3 3M Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.2 Johnson & Johnson (Janssen Pharmaceuticals Inc.)
16.2.1 Johnson & Johnson (Janssen Pharmaceuticals Inc.) Company Profile
16.2.2 Johnson & Johnson (Janssen Pharmaceuticals Inc.) Passive Transdermal Drug Delivery Product Specification
16.2.3 Johnson & Johnson (Janssen Pharmaceuticals Inc.) Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.3 Boehringer Ingelheim GmbH
16.3.1 Boehringer Ingelheim GmbH Company Profile
16.3.2 Boehringer Ingelheim GmbH Passive Transdermal Drug Delivery Product Specification
16.3.3 Boehringer Ingelheim GmbH Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.4 Actavis, Inc.
16.4.1 Actavis, Inc. Company Profile
16.4.2 Actavis, Inc. Passive Transdermal Drug Delivery Product Specification
16.4.3 Actavis, Inc. Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.5 GlaxoSmithKline plc
16.5.1 GlaxoSmithKline plc Company Profile
16.5.2 GlaxoSmithKline plc Passive Transdermal Drug Delivery Product Specification
16.5.3 GlaxoSmithKline plc Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.6 Bayer AG
16.6.1 Bayer AG Company Profile
16.6.2 Bayer AG Passive Transdermal Drug Delivery Product Specification
16.6.3 Bayer AG Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.7 Novartis AG
16.7.1 Novartis AG Company Profile
16.7.2 Novartis AG Passive Transdermal Drug Delivery Product Specification
16.7.3 Novartis AG Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.8 Echo Therapeutics, Inc.
16.8.1 Echo Therapeutics, Inc. Company Profile
16.8.2 Echo Therapeutics, Inc. Passive Transdermal Drug Delivery Product Specification
16.8.3 Echo Therapeutics, Inc. Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.9 Corium International, Inc.
16.9.1 Corium International, Inc. Company Profile
16.9.2 Corium International, Inc. Passive Transdermal Drug Delivery Product Specification
16.9.3 Corium International, Inc. Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.10 Mylan N.V.
16.10.1 Mylan N.V. Company Profile
16.10.2 Mylan N.V. Passive Transdermal Drug Delivery Product Specification
16.10.3 Mylan N.V. Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.11 Noven Pharmaceuticals, Inc.
16.11.1 Noven Pharmaceuticals, Inc. Company Profile
16.11.2 Noven Pharmaceuticals, Inc. Passive Transdermal Drug Delivery Product Specification
16.11.3 Noven Pharmaceuticals, Inc. Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
16.12 Transdermal Corp.
16.12.1 Transdermal Corp. Company Profile
16.12.2 Transdermal Corp. Passive Transdermal Drug Delivery Product Specification
16.12.3 Transdermal Corp. Passive Transdermal Drug Delivery Production Capacity, Revenue, Price and Gross Margin (2015-2020)
17 Passive Transdermal Drug Delivery Manufacturing Cost Analysis
17.1 Passive Transdermal Drug Delivery Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Passive Transdermal Drug Delivery
17.4 Passive Transdermal Drug Delivery Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Passive Transdermal Drug Delivery Distributors List
18.3 Passive Transdermal Drug Delivery Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Passive Transdermal Drug Delivery (2021-2026)
20.2 Global Forecasted Revenue of Passive Transdermal Drug Delivery (2021-2026)
20.3 Global Forecasted Price of Passive Transdermal Drug Delivery (2015-2026)
20.4 Global Forecasted Production of Passive Transdermal Drug Delivery by Region (2021-2026)
20.4.1 North America Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.2 East Asia Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.3 Europe Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.4 South Asia Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.5 Southeast Asia Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.6 Middle East Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.7 Africa Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.8 Oceania Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.9 South America Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.4.10 Rest of the World Passive Transdermal Drug Delivery Production, Revenue Forecast (2021-2026)
20.5 Forecast by Type and by Application (2021-2026)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2021-2026)
20.5.2 Global Forecasted Consumption of Passive Transdermal Drug Delivery by Application (2021-2026)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.2 East Asia Market Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.3 Europe Market Forecasted Consumption of Passive Transdermal Drug Delivery by Countriy
21.4 South Asia Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.5 Southeast Asia Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.6 Middle East Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.7 Africa Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.8 Oceania Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.9 South America Forecasted Consumption of Passive Transdermal Drug Delivery by Country
21.10 Rest of the world Forecasted Consumption of Passive Transdermal Drug Delivery by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer